背景反复输血或使用红细胞生成刺激剂(ESA)都可以用于治疗肾性贫血.但是对两种治疗方法的选择,应该针对患者的实际情况,根据两种治疗方法的相对利弊进行选择.单纯的Hb降低不作为输血的理由,不能为了Hb达标而输血.慢性贫血患者输血是为了防止组织缺氧或心力衰竭.在ESA治疗Hb达标的患者,仅在急性失血(如急性出血、急性溶血、严重炎症或外科血液丢失)时输血.输血患者患急性冠脉综合征时有更高的死亡率.使用输
Background.Recent clinical trials in cancer patients treated with erythropoiesis-stimulating agents (ESAs) and in CKD patients treated to haemoglobin (Hb) targets above the labeled range of 10-12 g/dL
Background and Objectives: Instability of hemoglobin levels during epoetin therapy is a new problem in hemodialysis.We evaluated extent and correlates of time in target, that is, the time spent with h
Background: Anaemia is a known risk factor for cardiovascular disease and treating anaemia in chronic kidney disease (CKD) may improve outcomes.However, little is known about the scope to improve prim
Objective-To determine whether recombinant human erythropoietin improves the quality of fife and exercise capacity of anaemic patients receiving haemodialysis.Design-A double blind, randomised, placeb
Haemoglobin (Hgb) levels are known to be associated with numerous adverse outcomes in both chronic kidney disease (CKD) and non-CKD patients.This analysis evaluates the association of baseline haemogl
Anemia associated with chronic renal insufficiency (CRI) may have substantial clinical and public health importance, butlittle is known about its epidemiology.This study aims to quantify the relations
Hemoglobin levels vary substantially over time in hemodialysis patients, and this variability may portend poor.outcomes.For a given patient, hemoglobin concentration over time can be described by abso
Background and objectives: Anemia and hemoglobin (Hb) variability are associated with mortality in hemodialysis patients who are on erythropoiesis-stimulating agents (ESA).Our aim was to describe the
Patients with CKD exhibit significant within-patient hemoglobin (Hb) level variability, especially with the use of erythropoiesis stimulating agents (ESAs) and iron.Analyses of dialysis cohorts in the